

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ARTGO HOLDINGS LIMITED

雅高控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3313)

STRATEGIC COOPERATION AGREEMENT

This announcement is made by Artgo Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business developments of the Group.

STRATEGIC COOPERATION AGREEMENT

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 9 March 2023 (after trading hours), the Company entered into a strategic cooperation agreement (the “**Agreement**”) with Jiangsu Daocheng Biotechnology Co., Ltd.* (江蘇道誠生物科技有限公司, “**Daocheng Biotechnology**”), a limited liability company established in the People’s Republic of China, pursuant to which the parties intend to carry out a cooperation (the “**Cooperation**”).

Pursuant to the Agreement, the parties have agreed to pursue a cooperation in multiple disciplines, including but not limited to brand cooperation, information sharing, collaboration in activities and consolidation of resources etc..

Daocheng Biotechnology is a limited liability company established in the People’s Republic of China (together with its subsidiaries, the “**Daocheng Group**”), which is mainly engaged in the research and development, production, processing and sales of healthcare food, food products, cosmetics and daily necessities. The core business strategy of **Daocheng Group** is to build a great health industry integrating herbal planting, research and development, production, sales, chain store operation, traditional Chinese medical institutions, leisure and health, healthcare, catering, accommodations and tourism. As at the date of this announcement, to the best of the knowledge, information and belief of the Directors having made all reasonable enquiry, **Daocheng Biotechnology** and its ultimate beneficial owner(s) are third parties independent of and not connected with the Company and its connected persons.

Except for the provisions in relation to binding effect, confidentiality and dispute resolution, which shall be binding upon the parties to the Agreement, other provisions set out in the Agreement are subject to the negotiation and execution of any formal agreement(s) and shall not be binding upon the parties to the Agreement.

The Cooperation is subject to, amongst others, the formal agreement(s). Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company. The Company will make further announcement in respect of the Cooperation as and when appropriate in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By Order of the Board
Artgo Holdings Limited
Wu Jing
Chairman and Executive Director

Hong Kong, 9 March 2023

** For identification purpose only and should not be regarded as the official English translation of the Chinese name. In the event of any inconsistency, the Chinese's name prevails.*

As at the date of this announcement, the executive Directors are Mr. Gu Weiwen, Mr. Zhang Jian, Ms. Wu Jing and Mr. Wan Jian; the non-executive Director is Mr. Gu Zengcai; and the independent non-executive Directors are Ms. Lung Yuet Kwan, Mr. Hui Yat On and Mr. Zhai Feiquan.